Trial Profile
Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose escalation study
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Temozolomide
- Indications Glioma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PARADIGM
- 01 Apr 2024 Results published in the International Journal of Radiation Oncology, Biology, Physics
- 05 Jun 2018 Results from OPARATIC, PARADIGM and PARADIGM-2 studies, presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 25 May 2018 Planned number of patients changed from 164 to 194.